Obinutuzumab vs PF-05280586

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Follicular Lymphoma

Shared mechanism: CD20 · full Follicular Lymphoma pipeline

Obinutuzumab

Marketed by Roche and partners

Approved in Follicular Lymphomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT03980171 (registry estimate)

No aligned efficacy figure on record for this race.

PF-05280586

Marketed by Pfizer

Approved in Follicular Lymphomabiologic (registry-typed, subtype undisclosed)
Reliable signal

NCT02213263 · Phase 3 · completed

The trial randomized 394 participants to PF-05280586 or active comparator MabThera and was double-blind. The primary endpoint was the clinical response rate at Week 26, and the prespecified equivalence margin was met because the 95% confidence interval for the response-rate difference (-4.16% to 13.47%) remained within the -16% to 16% limits.

Reported efficacy

Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) (met)

Result source: NCT02213263

Results for Follicular Lymphoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Obinutuzumab: registry results are on file for Follicular Lymphoma, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

PF-05280586
Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) NCT02213263 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Non-Hodgkin Lymphoma

Shared mechanism: CD20 · full Non-Hodgkin Lymphoma pipeline

Obinutuzumab

Marketed by Roche and partners

Phase 3 in Non-Hodgkin Lymphomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT02393157 (registry estimate)

No aligned efficacy figure on record for this race.

PF-05280586

Marketed by Pfizer

Approved in Non-Hodgkin Lymphomabiologic (registry-typed, subtype undisclosed)
Reliable signal

NCT02213263 · Phase 3 · completed

The trial randomized 394 participants to PF-05280586 or active comparator MabThera and was double-blind. The primary endpoint was the clinical response rate at Week 26, and the prespecified equivalence margin was met because the 95% confidence interval for the response-rate difference (-4.16% to 13.47%) remained within the -16% to 16% limits.

Reported efficacy

Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) (met)

Result source: NCT02213263

Results for Non-Hodgkin Lymphoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Obinutuzumab: registry results are on file for Non-Hodgkin Lymphoma, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

PF-05280586
Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) NCT02213263 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Chronic Lymphocytic Leukemia

Shared mechanism: CD20 · full Chronic Lymphocytic Leukemia pipeline

Obinutuzumab

Marketed by Roche and partners

Approved in Chronic Lymphocytic Leukemiamonoclonal antibody
Partial signal

NCT01010061 · Phase 3 · completed

Patients were randomly assigned to obinutuzumab plus chlorambucil or chlorambucil alone, but the study was open-label rather than double-blinded. The primary clinical endpoint, progression-free survival, was met, with 31.1 versus 11.1 months and p<0.0001; the substantial randomized sample supports reliable evidence, while the lack of blinding limits the overall strength rating.

Next expected readout: November 2026 · NCT04895436 (registry estimate)

No aligned efficacy figure on record for this race.

PF-05280586

Marketed by Pfizer

Approved in Chronic Lymphocytic Leukemiabiologic (registry-typed, subtype undisclosed)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Chronic Lymphocytic Leukemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Obinutuzumab: registry results are on file for Chronic Lymphocytic Leukemia, but their comparison mappings are not yet available.

PF-05280586: no structured comparison results are available for Chronic Lymphocytic Leukemia.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Obinutuzumab's landscape · PF-05280586's landscape